Plant-made anti-CHIKV antibodies use a uniform N-linked glycan profile to improve ADCC and neutralization while lowering ADE risk.
Targeted IL13RA2 and BIRC5 peptide immunotherapy aims to trigger cytotoxic T-cell responses against adrenal cancer and limit recurrence.
Plant-produced anti-CHIKV antibodies use a uniform N-linked glycan profile to improve neutralization while reducing ADE risk.
Optimized 3′ UTR double terminators and MARs boost transcript stability and raise plant recombinant protein expression.
Human anti-Ara h 2 antibodies block IgE binding and inflammatory mediator release, offering passive protection without oral immunotherapy.
This case uses a CD8α CAR and macrophage signaling domains to target EGFRvIII GBM cells while resisting M2 polarization.
Ex vivo expanded cytotoxic CD4+ T cells overcome low checkpoint inhibitor response rates by directly killing bladder cancer tumor cells.
Plant-produced chimeric antibodies combine parent variable regions with an engineered Fc domain to maintain efficacy against Omicron variants.
A geminiviral vector system expresses Rituximab heavy and light chains in Nicotiana benthamiana leaves.
A plant-based method uses a cleavable linking polypeptide to co-express antibody heavy and light chains for functional assembly.
Agrobacterium-mediated transgenic plants produce SARS-CoV-2 binding VHH antibodies, bypassing slow mammalian cell culture costs and contamination risks.
Glycoengineered plant cells produce monoclonal antibodies with defined N-glycoforms that maintain antigen binding affinity.
Treating plants with light and hormones increases secondary leaf biomass to boost recombinant protein production.
Co-expressing mammalian chaperones with target polypeptides to promote correct protein folding and oligomerization in plant cells.
A proteinase-engineered cancer vaccine alters cell surface patterns to induce targeted immune responses against malignant tumors.
A cross-linked biodegradable vesicle encapsulates oligonucleotide drugs via electrostatic interaction.
PhD9 antibody produced in Nicotiana benthamiana plants using transient expression systems.
Enzymatic removal of plant-specific fucose and xylose residues from glycan structures restores effector function and eliminates serum inhibition.
A geminivirus replicon system enables high-level expression of oligomeric protein complexes in plant cells.
High hydrostatic pressure kills tumor cells to trigger strong immune responses without adjuvants.
Standardized plant-based purification platform streamlines monoclonal antibody production via multi-step chromatography, eliminating virus inactivation costs.
A single expression vector integrates light and heavy chain cassettes with identical regulatory elements to drive coordinated protein synthesis.
Segmenting the gamma 134.5 gene preserves viral replication while eliminating neurovirulence, resolving safety-replication trade-offs.
A transgenic plant uses RNA interference to silence transferase enzymes and produce therapeutic proteins with reduced immunogenic glycans.
Co-expressing mammalian chaperones with heterologous polypeptides in plant cells to promote correct protein folding.